Detalhe da pesquisa
1.
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.
N Engl J Med
; 377(15): 1417-1427, 2017 10 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-28892457
2.
Relationship between P1NP, a biochemical marker of bone turnover, and bone mineral density in patients transitioned from alendronate to romosozumab or teriparatide: a post hoc analysis of the STRUCTURE trial.
J Bone Miner Metab
; 38(3): 310-315, 2020 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-31707465
3.
Correction to: Relationship between P1NP, a biochemical marker of bone turnover, and bone mineral density in patients transitioned from alendronate to romosozumab or teriparatide: a post hoc analysis of the STRUCTURE trial.
J Bone Miner Metab
; 38(4): 605, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32198616
4.
Romosozumab Treatment in Postmenopausal Women with Osteoporosis.
N Engl J Med
; 375(16): 1532-1543, 2016 10 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-27641143
5.
Do odour impact criteria of different jurisdictions ensure analogous separation distances for an equivalent level of protection?
J Environ Manage
; 240: 394-403, 2019 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30954662
6.
Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial.
Lancet
; 390(10102): 1585-1594, 2017 Sep 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-28755782
7.
Romosozumab in postmenopausal women with low bone mineral density.
N Engl J Med
; 370(5): 412-20, 2014 Jan 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-24382002
8.
Romosozumab versus Alendronate and Fracture Risk in Women with Osteoporosis.
N Engl J Med
; 378(2): 195-196, 2018 01 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-29320649
9.
Romosozumab Treatment in Postmenopausal Osteoporosis.
N Engl J Med
; 376(4): 396-7, 2017 01 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-28121504
10.
Validation of the Osteoporosis-Specific Morisky Medication Adherence Scale in long-term users of bisphosphonates.
Qual Life Res
; 23(7): 2109-20, 2014 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-24604077
11.
End Point Considerations for Clinical Trials in Enteric Hyperoxaluria.
Clin J Am Soc Nephrol
; 18(12): 1637-1644, 2023 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37342976
12.
Romosozumab in postmenopausal women with osteopenia.
N Engl J Med
; 370(17): 1664-5, 2014 04 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-24758630
13.
Psychometric properties of the Osteoporosis-specific Morisky Medication Adherence Scale in postmenopausal women with osteoporosis newly treated with bisphosphonates.
Ann Pharmacother
; 46(5): 659-70, 2012 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-22510666
14.
Compilation of a city-scale black carbon emission inventory: Challenges in developing countries based on a case study in Brazil.
Sci Total Environ
; 839: 156332, 2022 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35640756
15.
Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors.
Clin Cancer Res
; 28(15): 3214-3224, 2022 08 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35583817
16.
Romosozumab Enhances Vertebral Bone Structure in Women With Low Bone Density.
J Bone Miner Res
; 37(2): 256-264, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34738660
17.
Adrenal tumors provide insight into the role of cortisol in NK cell activity.
Endocr Relat Cancer
; 28(8): 583-592, 2021 06 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-34086600
18.
Binding of phosphorylated peptides and inhibition of their interaction with disease-relevant human proteins by synthetic metal-chelate receptors.
J Mol Recognit
; 23(3): 329-34, 2010.
Artigo
em Inglês
| MEDLINE | ID: mdl-19728300
19.
Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials.
Lancet Diabetes Endocrinol
; 8(8): 672-682, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32707115
20.
A Randomized, Placebo-Controlled Study of Romosozumab for the Treatment of Hip Fractures.
J Bone Joint Surg Am
; 102(8): 693-702, 2020 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31977817